All In Biotech

Drug Trial Radar · NCT07341828

A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Feb 2026

Primary completion

Jun 2027

Study completion Feb 2029

Sponsor

Lead sponsor
Huashan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai AbelZeta Ltd.
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy

Conditions

  • Multiple Sclerosis (MS)
  • Neuromyelitis Optica Spectrum Disorders (NMOSD)
  • Autoimmune Encephalitis
  • Stiff Person Syndrome

Interventions

  • CD20/BCMA-directed CAR-T cellsBiological

    Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Adverse Events [Safety and Tolerability]Time frame: Throughout the first 3 months follow up period completion
  2. The subsequent recommended dose of C-CAR168 in patients with central nervous system autoimmune diseases refractory to standard therapyTime frame: Throughout the first 24 months follow up period completion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.